These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 18713822)

  • 1. Fatty acid metabolism in patients with PPARgamma mutations.
    Tan GD; Savage DB; Fielding BA; Collins J; Hodson L; Humphreys SM; O'Rahilly S; Chatterjee K; Frayn KN; Karpe F
    J Clin Endocrinol Metab; 2008 Nov; 93(11):4462-70. PubMed ID: 18713822
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pparg-P465L mutation worsens hyperglycemia in Ins2-Akita female mice via adipose-specific insulin resistance and storage dysfunction.
    Pendse AA; Johnson LA; Tsai YS; Maeda N
    Diabetes; 2010 Nov; 59(11):2890-7. PubMed ID: 20724579
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of rosiglitazone on fatty acid and triglyceride metabolism in type 2 diabetes.
    Tan GD; Fielding BA; Currie JM; Humphreys SM; Désage M; Frayn KN; Laville M; Vidal H; Karpe F
    Diabetologia; 2005 Jan; 48(1):83-95. PubMed ID: 15619071
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Pharmacogenetic Approach to the Treatment of Patients With
    Agostini M; Schoenmakers E; Beig J; Fairall L; Szatmari I; Rajanayagam O; Muskett FW; Adams C; Marais AD; O'Rahilly S; Semple RK; Nagy L; Majithia AR; Schwabe JWR; Blom DJ; Murphy R; Chatterjee K; Savage DB
    Diabetes; 2018 Jun; 67(6):1086-1092. PubMed ID: 29622583
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New PPARG mutation leads to lipodystrophy and loss of protein function that is partially restored by a synthetic ligand.
    Lüdtke A; Buettner J; Schmidt HH; Worman HJ
    J Med Genet; 2007 Sep; 44(9):e88. PubMed ID: 17766367
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Familial partial lipodystrophy linked to a novel peroxisome proliferator activator receptor -γ (PPARG) mutation, H449L: a comparison of people with this mutation and those with classic codon 482 Lamin A/C (LMNA) mutations.
    Demir T; Onay H; Savage DB; Temeloglu E; Uzum AK; Kadioglu P; Altay C; Ozen S; Demir L; Cavdar U; Akinci B
    Diabet Med; 2016 Oct; 33(10):1445-50. PubMed ID: 26756202
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inguinal Fat Compensates Whole Body Metabolic Functionality in Partially Lipodystrophic Mice with Reduced PPARγ Expression.
    Chang CS; Yu SS; Ho LC; Chao SH; Chou TY; Shao AN; Kao LZ; Chang CY; Chen YH; Wu MS; Tsai PJ; Maeda N; Tsai YS
    Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835312
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterisation of non-obese diabetic patients with marked insulin resistance identifies a novel familial partial lipodystrophy-associated PPARγ mutation (Y151C).
    Visser ME; Kropman E; Kranendonk ME; Koppen A; Hamers N; Stroes ES; Kalkhoven E; Monajemi H
    Diabetologia; 2011 Jul; 54(7):1639-44. PubMed ID: 21479595
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical characteristics and efficacy of pioglitazone in a Japanese patient with familial partial lipodystrophy due to peroxisome proliferator-activated receptor γ gene mutation.
    Iizaka T; Kodama E; Mikura K; Iida T; Imai H; Hashizume M; Kigawa Y; Sugisawa C; Tadokoro R; Endo K; Otsuka F; Isoda M; Ebihara K; Ishibashi S; Nagasaka S
    Endocr J; 2023 Jan; 70(1):69-76. PubMed ID: 36171144
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peroxisome proliferator-activated receptor-γ in capillary endothelia promotes fatty acid uptake by heart during long-term fasting.
    Goto K; Iso T; Hanaoka H; Yamaguchi A; Suga T; Hattori A; Irie Y; Shinagawa Y; Matsui H; Syamsunarno MR; Matsui M; Haque A; Arai M; Kunimoto F; Yokoyama T; Endo K; Gonzalez FJ; Kurabayashi M
    J Am Heart Assoc; 2013 Jan; 2(1):e004861. PubMed ID: 23525438
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lessons from human mutations in PPARgamma.
    Hegele RA
    Int J Obes (Lond); 2005 Mar; 29 Suppl 1():S31-5. PubMed ID: 15711581
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peroxisome proliferator-activated receptor-gamma C190S mutation causes partial lipodystrophy.
    Lüdtke A; Buettner J; Wu W; Muchir A; Schroeter A; Zinn-Justin S; Spuler S; Schmidt HH; Worman HJ
    J Clin Endocrinol Metab; 2007 Jun; 92(6):2248-55. PubMed ID: 17356052
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insulin Sensitivity in Adipose and Skeletal Muscle Tissue of Dairy Cows in Response to Dietary Energy Level and 2,4-Thiazolidinedione (TZD).
    Hosseini A; Tariq MR; Trindade da Rosa F; Kesser J; Iqbal Z; Mora O; Sauerwein H; Drackley JK; Trevisi E; Loor JJ
    PLoS One; 2015; 10(11):e0142633. PubMed ID: 26571137
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Importance of changes in adipose tissue insulin resistance to histological response during thiazolidinedione treatment of patients with nonalcoholic steatohepatitis.
    Gastaldelli A; Harrison SA; Belfort-Aguilar R; Hardies LJ; Balas B; Schenker S; Cusi K
    Hepatology; 2009 Oct; 50(4):1087-93. PubMed ID: 19670459
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The in vivo effects of the Pro12Ala PPARgamma2 polymorphism on adipose tissue NEFA metabolism: the first use of the Oxford Biobank.
    Tan GD; Neville MJ; Liverani E; Humphreys SM; Currie JM; Dennis L; Fielding BA; Karpe F
    Diabetologia; 2006 Jan; 49(1):158-68. PubMed ID: 16362285
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adipose tissue fatty acid metabolism in insulin-resistant men.
    Bickerton AS; Roberts R; Fielding BA; Tornqvist H; Blaak EE; Wagenmakers AJ; Gilbert M; Humphreys SM; Karpe F; Frayn KN
    Diabetologia; 2008 Aug; 51(8):1466-74. PubMed ID: 18504545
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Familial partial lipodystrophy phenotype resulting from a single-base mutation in deoxyribonucleic acid-binding domain of peroxisome proliferator-activated receptor-gamma.
    Monajemi H; Zhang L; Li G; Jeninga EH; Cao H; Maas M; Brouwer CB; Kalkhoven E; Stroes E; Hegele RA; Leff T
    J Clin Endocrinol Metab; 2007 May; 92(5):1606-12. PubMed ID: 17299075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of the type 2 diabetes-associated PPARG P12A polymorphism on progression to diabetes and response to troglitazone.
    Florez JC; Jablonski KA; Sun MW; Bayley N; Kahn SE; Shamoon H; Hamman RF; Knowler WC; Nathan DM; Altshuler D;
    J Clin Endocrinol Metab; 2007 Apr; 92(4):1502-9. PubMed ID: 17213274
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systemic PPARγ deletion in mice provokes lipoatrophy, organomegaly, severe type 2 diabetes and metabolic inflexibility.
    Gilardi F; Winkler C; Quignodon L; Diserens JG; Toffoli B; Schiffrin M; Sardella C; Preitner F; Desvergne B
    Metabolism; 2019 Jun; 95():8-20. PubMed ID: 30878493
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human metabolic syndrome resulting from dominant-negative mutations in the nuclear receptor peroxisome proliferator-activated receptor-gamma.
    Savage DB; Tan GD; Acerini CL; Jebb SA; Agostini M; Gurnell M; Williams RL; Umpleby AM; Thomas EL; Bell JD; Dixon AK; Dunne F; Boiani R; Cinti S; Vidal-Puig A; Karpe F; Chatterjee VK; O'Rahilly S
    Diabetes; 2003 Apr; 52(4):910-7. PubMed ID: 12663460
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.